Controlled trial of bromocriptine, quinoestrol, and placebo in suppression of puerperal lactation.
2-bromo-alpha-ergocryptine (bromocriptine) in a dosage of 2-5 mg twice daily caused a rapid fall in plasma prolactin. It was more effective than either a single dose of 4 mg quinoestrol or a placebo in suppressing puerperal lactation, as judged by milk flow and the relief of breast pain and congestion. Patients who received quinoestrol were more comfortable than those who received placebo.
D001971:Bromocriptine / Q000008:administration & dosage / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004873:Ergolines / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007774:Lactation / Q000187:drug effects*; D008895:Milk, Human / Q000378:metabolism; D009651:Norpregnatrienes / Q000494:pharmacology*; D010919:Placebos; D011247:Pregnancy; D011388:Prolactin / Q000097:blood; D011800:Quinestrol / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors
D004873:Ergolines; D009651:Norpregnatrienes; D010919:Placebos; D001971:Bromocriptine; D011388:Prolactin; D011800:Quinestrol